NASDAQ:COLL Collegium Pharmaceutical Q3 2024 Earnings Results & Report $22.51 +0.98 (+4.55%) Closing price 10/14/2026 04:00 PM EasternExtended Trading$22.57 +0.06 (+0.25%) As of 10/14/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Collegium Pharmaceutical reported Q3 2024 earnings on January 8, 2025. The company reported EPS of $1.61, while revenue was $159.30 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2024Report DateJanuary 8, 2025TimeAfter Market Closes Collegium Pharmaceutical EPS ResultsActual EPS$1.61Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersCollegium Pharmaceutical Revenue ResultsActual Revenue$159.30 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsCollegium Pharmaceutical's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesEarnings HistoryCompany Profile Collegium Pharmaceutical Q3 2024 Earnings FAQ Did Collegium Pharmaceutical beat earnings estimates for Q3 2024? Collegium Pharmaceutical (NASDAQ:COLL) reported earnings of $1.61 per share for Q3 2024. The report was announced on Wednesday, January 8, 2025. What was Collegium Pharmaceutical's revenue for Q3 2024? Collegium Pharmaceutical reported revenue of $159.30 million for Q3 2024. When is Collegium Pharmaceutical's next earnings date? Collegium Pharmaceutical's next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Collegium Pharmaceutical on the company's earnings history page. Collegium Pharmaceutical Earnings HeadlinesCollegium Pharmaceutical Outlook Supported by ADHD Trends, Low Generic Drug Risk, Oppenheimer SaysOctober 9, 2026 | finance.yahoo.comCollegium Pharmaceutical (NASDAQ:COLL) Rating Lowered to "Strong Sell" at Zacks ResearchOctober 8, 2026 | americanbankingnews.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions. | Weiss Ratings (Ad)Collegium Pharmaceutical, Inc. Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday LifeOctober 6, 2026 | marketscreener.comMCollegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday LifeOctober 6, 2026 | globenewswire.comCollegium Pharmaceutical (NASDAQ:COLL) vs. Sanofi (NASDAQ:SNY) Critical SurveyOctober 6, 2026 | americanbankingnews.comSee More Collegium Pharmaceutical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Collegium Pharmaceutical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Collegium Pharmaceutical and other key companies, straight to your email. Email Address About Collegium PharmaceuticalCollegium Pharmaceutical (NASDAQ:COLL) is a specialty pharmaceutical company focused on developing, acquiring and commercializing medicines for central nervous system disorders. The company’s portfolio is concentrated in pain management and includes products for chronic and acute pain, opioid-induced constipation and related conditions. Collegium’s marketed products include Xtampza ER, an extended-release oxycodone formulation designed with the company’s DETERx abuse-deterrent technology; Nucynta and Nucynta ER, tapentadol products for acute and chronic pain; Belbuca, a buprenorphine buccal film for chronic pain; and Symproic, a treatment for opioid-induced constipation. The company also markets Jornay PM, an extended-release methylphenidate product for attention-deficit hyperactivity disorder. Founded in 2002 and headquartered in Stoughton, Massachusetts, Collegium primarily serves the U.S. specialty pharmaceutical market. Its growth strategy has included product acquisitions and portfolio expansion, including the acquisition of BioDelivery Sciences International and the purchase of Ironshore Therapeutics, which added Jornay PM to its commercial portfolio.View Collegium Pharmaceutical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
